Abstract: In recent years, significant progress has been made in breast cancer treatment. However, metastatic breast cancer continues to have a bleak prognosis, with 5-year survival rates dropping below 20%. Studies on tumor stress resistance have unveiled various crucial molecular elements. Notably, the uptake of extracellular vesicles (EV) has emerged as a critical factor in intracellular communication and advancing breast cancer metastasis. Moreover, the role of integrins, a class of cell surface receptors, in facilitating EV uptake and promoting cancer progression has gathered a significant amount of attention during these years of research. The ITG Vß3 dimer has been identified as a pivotal molecular entity involved in the uptake of EVs by breast cancer cells through endocytosis. This finding has streamlined in vitro and in vivo screening for specific inhibitors capable of delaying or preventing the progression of breast cancer metastasis. A high-throughput system has been refined to enable real-time monitoring of drugs that can inhibit EV uptake. In this project, a targeted single-chain variable fragment (scFv) has been successfully generated among the molecules disrupting the metastasis-promoting process. Preliminary trials with this scFv have shown promising outcomes, suggesting its potential to impede EV internalization and decrease metastatic dissemination. This inhibitor exhibits promising capabilities to intervene in the metastatic pathway.